Zwijnaarde, Belgium

Assay Development & Screening

Confo Therapeutics is the only GPCR company with a discovery engine that precisely targets desired GPCR conformations. This unique capability allows us to unlock a vast untapped potential for the discovery and development of breakthrough medicines. We are advancing a robust pipeline of large and small molecules focused on validated targets in endocrine and metabolic diseases, as well as addressing a broader array of critical unmet medical needs in collaboration with our partners. Our team of approximately 65 people is dedicated to advancing our technology, expanding our capabilities, and building out our pipeline in order to achieve the best possible therapeutic outcomes for patients.

Confo Therapeutics is located on the Technology Park in Ghent. More information about Confo’s technology and strategy can be found on www.confotherapeutics.com.

For the expansion of our R&D team we are currently looking for a:

Research Associate Assay Development and Screening team

Your responsibilities

• Work on the development of new screening assays to extend the Confo technology platform

• Develop, optimize and run high-throughput screening assays

• Validate assays on new targets towards drug discovery

• Run assay to support drug discovery programs using different techniques such as   cell based assays, HTRF, flow cytometry,  …

• Analyze and interpret your own research data and create reports using established software tools and systems

• Provide high-quality data on time and report results within electronic lab notebook

• Communicate/Present your experimental progress to line management and/or project teams

• Handle multiple projects in parallel with overlapping deadlines

• Degree of Professional Bachelor in Laboratory Technology or Biotechnology (Laboratory Technician A1), Bachelor or Master in Industrial Sciences (Industrial Engineer), Biochemistry, Biotechnology or equivalent

• Experience in a related field in biotech or pharma environment is a plus

• Experience in cell culture handling and performing protein binding assays and/or cellular assays would be an advantage

• Highly collaborative, self-motivated, team-oriented, problem-solving skilled individual

• Ability to work in a fast-paced, highly integrated team environment where accuracy, accountability and timeliness are essential

• Ability to keep accurate and complete records of all scientific experiments according to established procedures.

• You are fluent in English and can communicate research results to the team and cross-functional stakeholders across the company

Zwijnaarde, Belgium

Bio-Analysis

Confo Therapeutics is the only GPCR company with a discovery engine that precisely targets desired GPCR conformations. This unique capability allows us to unlock a vast untapped potential for the discovery and development of breakthrough medicines. We are advancing a robust pipeline of large and small molecules focused on validated targets in endocrine and metabolic diseases, as well as addressing a broader array of critical unmet medical needs in collaboration with our partners. Our team of approximately 60 people is dedicated to advancing our technology, expanding our capabilities, and building out our pipeline in order to achieve the best possible therapeutic outcomes for patients.

Confo Therapeutics is located on the Technology Park in Ghent. More information about Confo’s technology and strategy can be found on www.confotherapeutics.com.

For the expansion of our R&D team we are currently looking for a
(Senior) Scientist, Discovery Pharmacology.

This role requires significant expertise in in vivo drug profiling and pharmacokinetics (DMPK) sciences, offering a unique opportunity for the successful candidate to play a pivotal part in discovering and developing new therapeutics for endocrine and metabolic diseases.

Key Responsibilities

• Design, plan, and supervise in vivo PK and preclinical studies promptly to advance drug molecules (small molecule and antibody) across various indications within endocrine and metabolic diseases.

• Develop and lead DMPK, modeling, and simulation strategies to support the progression of drug candidates (small molecule and antibody) from discovery through development.

• Collaborate closely with other departments (biology, chemistry, bioanalysis, screening, clinical development, etc.) and external partners (CROs) to align objectives and produce meaningful DMPK and in vivo efficacy data that guide target validation, compound characterization, and candidate selection.

• Conduct quality control analyses on in vivo and DMPK data generated by CROs.

• Analyze, interpret, and clearly communicate DMPK data, provide expert opinions, and support project decision-making to ensure pipeline progress.

• Stay informed about advances in DMPK research and integrate new concepts as appropriate.

• PhD (or equivalent) in Pharmacology, Biomedical Sciences, or a related field, plus at least four years of industry experience.

• Possess a deep understanding of drug metabolism, distribution, and excretion; experience with both small molecules and antibodies is advantageous.

• Extensive background in preclinical and clinical DMPK in an industrial setting, with a proven record of scientific accomplishments.

• Comprehensive knowledge of ADME sciences, drug metabolism, pharmacokinetics, bioanalysis, PKPD principles, human PK, and familiarity with industry-standard software.

• Experience with various therapeutic modalities is considered a strong asset.

• Outstanding communication and presentation abilities.

• Strong leadership skills, with the capacity to influence others and make decisions.

• Proven ability to work effectively in a matrix environment, manage multiple projects, and handle shifting priorities.

Zwijnaarde, Belgium

Didn’t find what you are looking for, but our website has sparked your interest?

We are always looking for great talent, and we would love to hear from you.

Please submit your CV/resume and a covering letter explaining why you are interested in joining Confo Therapeutics.